Answers are grounded in this paper and cite their sources.
Central Asia is undergoing rapid epidemiological transition, yet internationally comparable assessments of cancer profiles in the constituent countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan) remain limited. We aimed to describe patterns of cancer incidence and mortality across the region and to project the future cancer burden through 2045. Cancer incidence and mortality estimates in 2022 were obtained for the five countries from IARC's GLOBOCAN database. Age-standardised incidence and mortality rates were compared by country, sex and cancer type. The future cancer burden was projected by applying age-specific cancer rates to population projections, assuming stable rates over time. In 2022, an estimated 92,665 new cancer cases and 56,110 cancer deaths occurred across Central Asia. Kazakhstan had the highest overall incidence and mortality rates, whereas the lowest rates across most major cancer sites were consistently estimated for Tajikistan. Breast cancer was the most common cancer among women, and lung cancer among men. The regional cancer profile was characterised by the coexistence of infection-related cancers alongside those linked to socioeconomic transition. Assuming stable rates, the annual number of new cancer cases is projected to increase by approximately 65%, reaching 152,000 by 2045, while cancer deaths are projected to increase by 73% to nearly 97,000 deaths. Cancer patterns in Central Asia suggest that regional cancer control planning should be nuanced to reflect each country's profile and resources, balancing prevention of infection-related cancers with early detection and effective management of common cancers associated with ongoing socioeconomic transitions.
No takes yet. Share an insight, caveat, or question.
Chkhaberidze et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: